BioMarin Pharmaceuticals
BMRN
BMRN
422 hedge funds and large institutions have $15.4B invested in BioMarin Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 175 increasing their positions, 120 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
422
Holders Change
+31
Holders Change %
+7.93%
% of All Funds
11.28%
Holding in Top 10
13
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.35%
New
66
Increased
175
Reduced
120
Closed
32
Calls
$127M
Puts
$124M
Net Calls
+$3.04M
Net Calls Change
-$11.5M
Top Buyers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$404M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$75.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$64.9M |
| 5 |
Jennison Associates
New York
|
+$60.2M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$91.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$86.8M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$64.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$63M |
| 5 |
HM
HealthCor Management
New York
|
-$58.4M |
